8-K: SS Innovations Completes Re-Audit, Withdraws S-1 Filing, and Plans Nasdaq Uplisting

SS Innovations has completed a re-audit of its financial statements, withdrawn its S-1 registration, and is moving forward with plans to uplist to Nasdaq.

Summary

• SS Innovations' new auditor, BDO India LLP, has completed a re-audit of the company's financial statements for 2022 and 2023.
• The re-audit was necessary after the previous auditor, BF Borgers CPA PC, was barred from practicing before the SEC.
• An internal review and external consulting engagement revealed material errors in the original financial statements, leading to a restatement.
• The restated financials, filed on December 6, 2024, show an increase in shareholders' equity by $5.42 million and working capital surplus by $3.85 million.
• The company has withdrawn its pending S-1 registration statement filed on February 14, 2024.
• SS Innovations intends to uplist its common stock to Nasdaq or another national securities exchange as soon as possible.
• The company has completed over 2,500 robotic surgical procedures, primarily in India, and has expanded to Indonesia.
• SS Innovations expects to receive FDA approval and CE Mark approval in the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the completion of the re-audit, improved financials, and plans for Nasdaq uplisting, but tempered by the need for a restatement and withdrawal of the S-1 filing.

Positives

• The re-audit by BDO has been completed, resolving the issue with the previous auditor.
• The restated financials show an improved net worth position and slightly improved financial performance for 2023.
• The company is actively pursuing an uplisting to Nasdaq, which could increase visibility and access to capital.
• SS Innovations has demonstrated significant growth with over 2,500 robotic surgical procedures completed.
• The company is expanding its global presence, including a recent expansion to Indonesia.
• The company is progressing with regulatory approvals in the US and Europe.

Negatives

• The need for a re-audit and restatement of financials indicates prior accounting errors.
• The withdrawal of the S-1 registration statement may delay capital raising plans.
• The company had to terminate its previous auditor due to SEC action.

Risks

• The company faces risks associated with regulatory approvals in the US and Europe.
• The company's future financial performance is subject to various risks and uncertainties.
• The company's ability to successfully uplist to Nasdaq is not guaranteed.
• The company's expansion plans may face challenges in new markets.

Future Outlook

SS Innovations intends to uplist to Nasdaq or another national securities exchange as soon as possible and anticipates receiving FDA and CE Mark approvals in the second half of 2025.

Management Comments

• SS Innovations believes that it meets the requirements for listing its shares of common stock on NASDAQ without completing the offering contemplated by the Registration Statement.
• The company plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally.

Industry Context

The announcement comes amid increasing interest in robotic surgery and the need for more affordable and accessible solutions. SS Innovations is positioning itself to compete with established players by offering a cost-effective alternative.

Comparison to Industry Standards

• Intuitive Surgical, a leader in robotic surgery, has a significant market share, but SS Innovations is targeting a different market segment with its focus on affordability.
• Globally, robotic surgery adoption is increasing, with companies like Medtronic and Stryker also investing in this space.
• SS Innovations' 2,500 completed procedures is a significant milestone, but it is still relatively small compared to the procedure volumes of established players.
• The company's expansion into Indonesia is a positive step, but it needs to demonstrate sustained growth and market penetration in new regions.
• The anticipated FDA and CE Mark approvals are crucial for the company's expansion into developed markets.

Stakeholder Impact

• Shareholders will benefit from the improved financial position and potential Nasdaq uplisting.
• Employees may see increased opportunities as the company expands.
• Customers will have access to more affordable robotic surgery options.
• Suppliers may see increased demand for their products and services.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• SS Innovations will proceed with an uplisting to Nasdaq or another National Securities Exchange.
• The company will continue its expansion to fulfill its mission to provide affordable state-of-the-art robotic surgery treatment to patients around the globe.
• SS Innovations will continue the regulatory approval process in the United States and the European Union.

Key Dates

Keywords

robotic surgery, financial restatement, BDO India LLP, Nasdaq uplisting, surgical robotics, audit, SSi Mantra, FDA approval, CE Mark, healthcare technology